# Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty

> **NCT02820324** · PHASE3 · COMPLETED · sponsor: **Trevena Inc.** · enrollment: 407 (actual)

## Conditions studied

- Acute Pain

## Interventions

- **DRUG:** Oliceridine
- **DRUG:** Placebo
- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT02820324
- **Lead sponsor:** Trevena Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 407 (ACTUAL)
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02820324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02820324, "Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02820324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*